Meyahealth
HomeGeneticsConditionSialidosis
Back to Condition
Sialidosis
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Sialidosis

Sialidosis is a rare inherited lysosomal storage disorder caused by NEU1 gene mutations, leading to vision loss, muscle twitches, skeletal abnormalities, and neurological decline.

Overview

Sialidosis is a severe inherited metabolic condition that damages tissues and organ systems throughout the body, particularly the central nervous system. It belongs to a group of conditions known as lysosomal storage disorders. The disease is categorized into two major forms—Type I and Type II—which are defined by the age when symptoms first arise and the overall severity of the condition.

Types and Symptoms

Sialidosis Type I

Also known as cherry-red spot myoclonus syndrome, Type I is the less severe manifestation of sialidosis. Symptoms generally emerge during an individual's teenage years or early twenties and do not affect normal intelligence or lifespan. Key signs include:

  • Movement and Coordination Difficulties: Early signs include gait disturbances, difficulty coordinating voluntary movements (ataxia), leg tremors, and muscle twitches (myoclonus). Over time, myoclonus worsens, impairing the ability to sit, stand, or walk, eventually requiring wheelchair assistance.
  • Seizures: Recurrent seizure episodes.
  • Vision Loss: Progressive decline in sharp vision (reduced visual acuity), night blindness, and impaired color perception.
  • Cherry-Red Spot: A characteristic abnormal red spot in the retina of the eye identifiable via ophthalmic examination.

Sialidosis Type II

Type II is a much more severe form of the disease that presents earlier in life and is broken down into three subtypes:

  • Congenital Form: Begins prior to birth. Fetuses may present with widespread fluid accumulation throughout the body (hydrops fetalis) or fluid collection within the abdominal cavity (ascites). Other findings include an enlarged liver and spleen (hepatosplenomegaly) and abnormal skeletal development (dysostosis multiplex). Affected infants are typically stillborn or die shortly after birth.
  • Infantile Form: Signs appear during the first year of life. Features include dysostosis multiplex, hepatosplenomegaly, "coarse" facial features, short stature, and intellectual disability. As children age, they can develop myoclonus, cherry-red spots, hearing loss, and overgrowth of the gums. Survival into childhood or adolescence is possible.
  • Juvenile Form: The least severe variant of Type II, typically manifesting in late childhood. Signs include mildly coarse facial features, mild bone defects, dark red skin spots (angiokeratomas), myoclonus, cherry-red spots, and intellectual disability. Life expectancy varies based on symptom severity.

Frequency

The global prevalence of sialidosis remains unknown. However, sialidosis type I is observed more frequently among individuals of Italian descent.

Causes & Genetics

Sialidosis is caused by genetic mutations within the NEU1 gene. This gene directs the production of an enzyme called neuraminidase 1 (NEU1), which operates inside cellular recycling centers called lysosomes.

Within lysosomes, NEU1 is responsible for removing sialic acid from large sugar molecules attached to specific proteins. When NEU1 mutations occur, the resulting deficiency of the enzyme prevents normal breakdown, causing sialic acid-containing compounds to abnormally build up within the cell:

  • Type I: Associated with mutations that allow the production of some partially functional NEU1 enzyme.
  • Type II: Caused by mutations that eliminate or drastically reduce NEU1 enzyme activity.

The exact mechanism connecting this molecular accumulation to the specific bodily symptoms of the disease remains under investigation.

Inheritance

Sialidosis is passed down via an autosomal recessive inheritance pattern. An affected person inherits a mutated copy of the NEU1 gene from each parent. Parents of an individual with an autosomal recessive disorder carry one mutated allele but usually display no symptoms of the condition.

Other Names

  • Cherry red spot myoclonus syndrome
  • Mucolipidosis I
  • Mucolipidosis type I
  • Myoclonus cherry red spot syndrome

Frequently Asked Questions

Treat the episode as a seizure emergency. Ensure the person is in a safe position, protect them from injury, and do not restrain movements. If the seizure lasts longer than 5 minutes, if there are repeated seizures without regaining consciousness, or if breathing becomes abnormal, call emergency services (911). At the hospital, clinicians may administer benzodiazepines or other anti‑myoclonic agents and assess for triggers such as infection, fever, or medication changes. Prompt treatment can prevent injury and reduce the risk of status epilepticus.
Testing usually starts with a blood sample for DNA sequencing of the NEU1 gene, often ordered by a clinical geneticist. If pathogenic variants are identified, carrier testing can be offered to parents and siblings. For family planning, options include pre‑implantation genetic diagnosis (PGD) with IVF to select embryos without the disease‑causing mutations, or prenatal testing (chorionic villus sampling or amniocentesis) to determine fetal status. Genetic counseling is recommended to discuss recurrence risk (typically 25 % for autosomal recessive inheritance) and reproductive choices.
Look for subtle gait instability, frequent stumbling, or difficulty with fine motor tasks such as buttoning clothes. Early myoclonus may appear as brief, involuntary jerks of the arms or legs, especially when the person is startled. Some teens notice increased sensitivity to bright lights or trouble distinguishing colors, even if visual acuity is still normal. Reporting these changes promptly can lead to ophthalmologic and neurologic evaluation, retinal imaging for a cherry‑red spot, and enzyme testing for NEU1 activity.
No disease‑modifying cure exists, but supportive care can help. A balanced diet rich in antioxidants (berries, leafy greens, omega‑3 fatty acids) may modestly protect neurons. Some clinicians trial low‑dose pyridoxine (vitamin B6) or riboflavin, though evidence is limited. Regular physiotherapy, occupational therapy, and speech therapy are essential to maintain function. Anticonvulsants such as valproate, levetiracetam, or clonazepam are commonly used to control myoclonus and seizures. Always discuss any supplement or medication changes with a metabolic specialist.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ